If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
ERYTECH Pharma (Euronext: ERYP; Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells (RBCs), today announces the clearance of a U.S. patent application relating to the use of arginine deiminase (ADI) encapsulated in erythrocytes for the treatment of arginase-1 deficiency (A1D), a rare and debilitating metabolic disease. The claims also relate to the treatment of other indications, including arginine-dependent cancers, septic shock and diseases associated with angiogenesis.